20 April 2021
When the ongoing coronavirus pandemic broke out at the start of 2020, Swiss Rockets AG set itself the challenge of manufacturing a vaccine that activates multiple lines of immune system defense to combat SARS-CoV-2 most effectively. To achieve this mission, it founded the Basel-based subsidiary RocketVax AG in the summer of 2020. To start working on this challenging mission, the company successfully brought together globally leading experts in the fields of infectious diseases, immunology, virology, and genetic chemistry from the University of Basel, the University of Zurich, the ETH Zurich, the University Hospital of Basel and the Swiss Tropical and Public Health Institute in Basel, a globally leading institute in the field. This novel research approach also deployed an innovative synthetic DNA technology to manufacture complete SARS-CoV-2 viruses that had been weakened in a targeted manner.
Serbia is one of the countries that have been badly affected by pandemics. Therefore, Serbian journalists are keeping up with information and achievements regarding COVID-19 vaccines constantly, in order to inform the public about every possible solution. They are particularly curious about RocketVax’s COVID-19 vaccine development since the CEO of the company, Dr. Vladimir Cmiljanovic, was born and raised in Serbia.
Dr. Vladimir Cmiljanovic gave an interview for Serbian “Telegraf”, explaining the benefits of RVX-13, RocketVax’s SARS-CoV-2 vaccine.
To read the full article click on the file below.
22 April 2021
“There is light at the end of the tunnel. Progress is being made in vaccines against SARS-CoV-2, if somewhat slowly, particularly in Switzerland. They promise a return to normality, though they are not without setbacks. The vector vaccines developed by AstraZeneca and Johnson & Johnson are under fire following cases of thrombosis in younger women. […]
21 April 2021
Dr. Vladimir Cmiljanovic, CEO of RocketVax, gave an interview to Swiss SRF 1 radio about the progress of RVX-13 – a second-generation SARS-CoV-2 vaccine: Source: SRF 1 Radio The most important differences between RVX-13, RocketVax’s SARS-CoV-2 vaccine, and the first-generation vaccines are as follows: 1. RVX-13 induces a comprehensive activation of the immune system. Unlike […]
09 April 2021
CEO of RocketVax, Dr. Vladimir Cmiljanovic, explains for Kanal 5 TV Macedonia his opinion on how China has managed to control the pandemic rapidly and effectively. During the interview, Dr. Cmiljanovic also talked about the development of the second-generation SARS-CoV-2 vaccine, RVX-13, that will provide long-lasting immunity. “The first reason is that the socialist system […]
16 March 2021
CEO of RocketVax, Dr. Vladimir Cmiljanovic, gave an interview about the development of the second-generation SARS-CoV-2 vaccine for RTS (Serbian Broadcasting Corporation). “The first-generation vaccines are focused on one of the virus’s proteins – the so-called spike protein. They train our immune system by exposing the coronavirus spike protein to our immune cells. The so […]
09 February 2021
The Rocket Vaccine against the coronavirus will be the most effective in the defense against this vicious disease because it is the only one containing the actual, synthetically generated virus. A team of experts from Switzerland, led by Dr. Vladimir Cmiljanovic, deserves credit for that invention. What is the progress of the clinical trials? When […]